Evidence map›Paper›PMID 39822985›Full record

ArticleOpen medicine (Warsaw, Poland)2025

CMSP exerts anti-tumor effects on small cell lung cancer cells by inducing mitochondrial dysfunction and ferroptosis.

Xi Yan, Yinghao Niu, Yaojie Wang, Sisi Wei, Lina Han, Zhongyu Guo, Lianmei Zhao, Feng Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xi YanDepartment of Clinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Yinghao NiuDepartment of Clinical Biobank, The First Hospital of Hebei Medical University, Shijiazhuang, 050031, China.
Yaojie WangResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Sisi WeiResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Lina HanResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Zhongyu GuoDepartment of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Lianmei ZhaoResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Feng GaoDepartment of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aims to investigate the role and mechanism of Methods: The impact of CMSP on ferroptosis in H1688 and SW1271 cells was assessed through cell experiments and biological information analysis. Moreover, the expression of heme oxygenase 1 (HMOX1) in SCLC tissue was examined. Results: Following CMSP treatment, a concentration-dependent increase in cell death was observed, and differentially expressed genes were found to be associated with ferroptosis. CMSP notably facilitated ferroptosis events, such as elevated levels of reactive oxygen species (ROS), Fe Conclusion: CMSP triggers mitochondrial dysfunction via HMOX1 activation, leading to ferroptosis in SCLC cells, underscoring its potential as a therapeutic agent for SCLC.

Indexed as

ferroptosisHMOX1mitochondrial dysfunctionp-hydroxyl cinnamaldehyde, CMSPSCLC

Identifiers

PMID39822985
PMCPMC11737370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.